Pretty excited about this one 
I was on the Fentrepid clinical trial for PPMS.
Short answer - it worked! Better than ocrelizumab, with fewer side effects.
Except one. 
Around 3% of trialists reported spikes in liver function tests and unfortunately I was one of the 3%. Lots of tests in early part of trial to identify the problem and I was only on it for 4 months as a result. Went onto ocrelizumab afterwards and not as effective but at least it wasn’t killing my liver.
Officially the trial is double-blind in that you were either on Fenebrutinib or Ocrelizumab with the other product being a placebo, but in my case the liver function test results were so starkly obvious, it was clear which one I was on.
Gutted! Easy to take too. Daily tablets instead of 6-monthly IV infusion.
Article mentions FDA and it’s not yet approved - in fact the data is still being collated & analysed. And then NICE need to look at it for UK approval which could be on a separate timeline. Could be a couple more years yet before NHS patients are receiving their tablets. Hopefully sooner, we’ll see.
If your liver isn’t affected by it, Fenebrutinib will be worth the wait 
Graeme
2 Likes
This is Prof G’s take on it.
Breaking news: Fenebrutinib Press Release
2 Likes